Product Information

PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $3.0751 per EA under NDC 00480229956. Its NADAC has been published 62 times since Sep 17, 2025.

FDA first approved this application on Jun 25, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE

Phentermine and topiramate
$3.0751per EA
DEA Schedule CIV

Strength

11.25; 69 mg/1; mg/1

NDC

00480229956

Classification

Generic

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

11/18/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA204982

FDA Approved

6/25/2024

TE Code

AB

On Market Since

5/7/2025

Pharmacological Classes

Appetite Suppression
Cytochrome P450 2C19 Inhibitors
Cytochrome P450 3A4 Inducers
Decreased Central Nervous System Disorganized Electrical Activity
Increased Sympathetic Activity
Sympathomimetic Amine Anorectic

Price Statistics

The NADAC for PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE has been published 62 times since Sep 17, 2025, and over the history we have for it it has declined 30.2%. The table below summarizes its recorded NADAC range and movement.

Current price$3.0751 per EA
All-time high$4.4066 (Oct 15, 2025)
All-time low$3.0220 (Oct 21, 2026)
52-week high$4.2988
52-week low$3.0220
Median price$3.2090
Average price$3.5240
Largest weekly change-13.4% (Feb 18, 2026)
Weeks tracked62
Tracking sinceSep 17, 2025

Price History

1W

+1.8%

1M

-0.5%

3M

-2.2%

6M

-4.2%

1Y

-28.5%

3Y

N/A

5Y

N/A

All

-30.2%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Phentermine and topiramate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $3.0751 per EA (NDC 00480229956), effective Nov 18, 2026.

How has the price of PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE has declined 30.2%. It has been tracked across 62 weekly CMS publications since Sep 17, 2025.

What are the highest and lowest recorded NADAC prices for PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE?

Since Sep 17, 2025, the NADAC for PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE has ranged from a low of $3.0220 (Oct 21, 2026) to a high of $4.4066 (Oct 15, 2025), with a median of $3.2090 per EA.

Are there cheaper alternatives to PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE?

No other NADAC-published product currently shares the active ingredient and strength of PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE?

PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE (NDC 00480229956) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.